An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
ADC Therapeutics Announces Medical Leadership Transition
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
management
Rhea-AI Summary
ADC Therapeutics (NYSE: ADCT) announced the departure of Chief Medical Officer Jay Feingold, who is leaving to pursue a new opportunity. He played a crucial role in the growth of the company, particularly in the development of ZYNLONTA, its first commercial therapy. Joseph Camardo has been appointed as the new Chief Medical Officer, bringing extensive experience from previous roles at Celgene and Wyeth. Camardo's leadership is expected to ensure continuity in clinical development as the company advances its proprietary antibody drug conjugates for treating cancer.
Positive
Appointment of Joseph Camardo as Chief Medical Officer is expected to provide fresh leadership and continuity in clinical development.
Camardo's background in clinical development aligns with ADC Therapeutics' pipeline, including ZYNLONTA and other ADCs.
Negative
Departure of Jay Feingold may create concerns regarding leadership continuity and experience gaps within the clinical team.
LAUSANNE, Switzerland--(BUSINESS WIRE)--
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, announced today that Jay Feingold, MD, PhD, Senior Vice President and Chief Medical Officer, will depart the company to pursue a new opportunity. ADCT is pleased to announce that Joseph Camardo, MD, will be appointed Senior Vice President and Chief Medical Officer.
“Jay Feingold has played a key role in the growth of ADC Therapeutics over the last seven years and was instrumental in establishing our clinical team and strategy leading to the approval of our first commercial therapy, ZYNLONTA®,” said Chris Martin, PhD, Chief Executive Officer. “We are grateful for his leadership, expertise and steadfast dedication to patients, and we wish him well in his next endeavor.” Dr. Feingold will continue to consult with ADCT through 2022 to ensure a smooth transition.
Dr. Camardo joined ADC Therapeutics from Celgene Corporation, where he was most recently Senior Vice President of Celgene Global Health after having served as Senior Vice President of Global Medical Affairs and Corporate Medical Operations. Prior to Celgene, Dr. Camardo was Senior Vice President of Clinical Development and Medical Affairs at Forest Research Institute and spent more than 20 years at Wyeth Research before its acquisition by Pfizer. At Wyeth, he held several leadership roles including Senior Vice President of Clinical Research and Development.
“Dr. Camardo’s extensive background in clinical development and Medical Affairs makes him the ideal successor and ensures a seamless evolution of our company. Dr. Camardo worked closely with Dr. Feingold for the last 18 months and together they ensured our first marketed product was well-received by the physician community in the United States and beyond,” continued Chris Martin.
“On behalf of the Board of Directors, I am delighted to welcome Dr. Camardo to the pivotal role of Chief Medical Officer,” said Ron Squarer, Chairman of the Board and an advisor to the company. “The Board has worked closely with Joe Camardo on several critical projects and appreciates his vast and deep industry experience, as well as his passion for patients.”
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs). The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.
ADC Therapeutics’ CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large b-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents. Cami (camidanlumab tesirine) is being evaluated in a late-stage clinical trial for relapsed or refractory Hodgkin lymphoma and in a Phase 1b clinical trial for various advanced solid tumors. In addition to ZYNLONTA and Cami, ADC Therapeutics has multiple PBD-based ADCs in ongoing clinical and preclinical development.
ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit https://adctherapeutics.com/ and follow the Company on Twitter and LinkedIn.
ZYNLONTA® is a registered trademark of ADC Therapeutics SA.
What prompted Jay Feingold's departure from ADC Therapeutics?
Jay Feingold is leaving ADC Therapeutics to pursue a new opportunity, with the company expressing gratitude for his contributions.
Who is Joseph Camardo in relation to ADC Therapeutics?
Joseph Camardo has been appointed as the new Chief Medical Officer, succeeding Jay Feingold.
How does Joseph Camardo's background benefit ADC Therapeutics?
Camardo's extensive experience in clinical development and his previous roles at Celgene and Wyeth are expected to enhance ADC Therapeutics' capabilities.
What is the impact of leadership changes on ADC Therapeutics' operations?
The leadership change may influence the strategic direction and clinical development of ADC Therapeutics, particularly in advancing its cancer treatment pipeline.
